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IMPORTANCE Infection is frequent among patients in the intensive care unit (ICU).
Contemporary information about the types of infections, causative pathogens, and outcomes
can aid the development of policies for prevention, diagnosis, treatment, and resource
allocation and may assist in the design of interventional studies.
OBJECTIVE To provide information about the prevalence and outcomes of infection and the
available resources in ICUs worldwide.
DESIGN, SETTING, AND PARTICIPANTS Observational 24-hour point prevalence study with
longitudinal follow-up at 1150 centers in 88 countries. All adult patients (aged 18 years)
treated at a participating ICU during a 24-hour period commencing at 08:00 on September
13, 2017, were included. The final follow-up date was November 13, 2017.
EXPOSURES Infection diagnosis and receipt of antibiotics.
MAIN OUTCOMES AND MEASURES Prevalence of infection and antibiotic exposure
(cross-sectional design) and all-cause in-hospital mortality (longitudinal design).
RESULTS Among 15 202 included patients (mean age, 61.1 years [SD, 17.3 years]; 9181 were
men [60.4%]), infection data were available for 15 165 (99.8%); 8135 (54%) had suspected or
proven infection, including 1760 (22%) with ICU-acquired infection. A total of 10 640
patients (70%) received at least 1 antibiotic. The proportion of patients with suspected or
proven infection ranged from 43% (141/328) in Australasia to 60% (1892/3150) in Asia and
the Middle East. Among the 8135 patients with suspected or proven infection, 5259 (65%)
had at least 1 positive microbiological culture; gram-negative microorganisms were identified
in 67% of these patients (n = 3540), gram-positive microorganisms in 37% (n = 1946), and
fungal microorganisms in 16% (n = 864). The in-hospital mortality rate was 30%
(2404/7936) in patients with suspected or proven infection. In a multilevel analysis,
ICU-acquired infection was independently associated with higher risk of mortality compared
with community-acquired infection (odds ratio [OR], 1.32 [95% CI, 1.10-1.60]; P = .003).
Among antibiotic-resistant microorganisms, infection with vancomycin-resistant
Enterococcus (OR, 2.41 [95% CI, 1.43-4.06]; P = .001), Klebsiella resistant to β-lactam
antibiotics, including third-generation cephalosporins and carbapenems (OR, 1.29 [95% CI,
1.02-1.63]; P = .03), or carbapenem-resistant Acinetobacter species (OR, 1.40 [95% CI,
1.08-1.81]; P = .01) was independently associated with a higher risk of death vs infection with
another microorganism.
CONCLUSIONS AND RELEVANCE In a worldwide sample of patients admitted to ICUs in
September 2017, the prevalence of suspected or proven infection was high, with a substantial
risk of in-hospital mortality.
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I nfection is a common occurrence among patients in the in-tensive care unit (ICU) and a prerequisite to the develop-ment of sepsis.1 Since 2009, several studies have pro-
vided national and international epidemiological data on
sepsis,2-6 but fewer studies have specifically concentrated
on the underlying infections. Detailed data from around the
world on types of infection, including causative microorgan-
isms, as well as on the use and availability of diagnostic and
treatment options are important because they can help in-
crease and maintain awareness among clinicians, patients, and
caregivers about the effects of infections; identify risk factors
for infection; aid in the development of focused policies for
diagnosis and treatment; facilitate adequate and appropriate
resource allocation; assist in the design of interventional stud-
ies; and provide a baseline against which changes in patient
characteristics and the effects of new treatments or manage-
ment programs can be assessed over time.
In 1992, the European Prevalence of Infection in Inten-
sive Care (EPIC I) study was conducted in western European
ICUs.7 On the study day, 45% of patients had suspected or
proven infection and 62% were receiving antibiotics (prophy-
lactic or therapeutic). In 2007, a study of similar design but ex-
tending inclusion to ICUs worldwide (Extended Prevalence of
Infection in Intensive Care [EPIC II]) was conducted.8 On the
study day, 51% of the patients had suspected or proven infec-
tion and 71% were receiving prophylactic antibiotics, thera-
peutic antibiotics, or both types of antibiotics.
The current EPIC III study (Extended Study on Preva-
lence of Infection in Intensive Care III) was conducted in 2017
using a similar design to the earlier studies, but also included
questions related to the availability of specific resources for
the diagnosis and treatment of infection. It was hypothesized
that the prevalence of infection and the associated outcomes
would vary among geographic regions.
Methods
Study Design
This was an observational, cross-sectional, 24-hour point
prevalence study that used a similar study design to that used
in the previous EPIC studies.7,8 An international steering com-
mittee was established with representatives from 5 conti-
nents who were selected for their acknowledged expertise in
the field of intensive care infections (eAppendix 1 in the Supple-
ment). With support from the World Federation of Societies
of Intensive and Critical Care Medicine, emails were sent to
members of national intensive care societies, to contacts of the
steering committee members, and to more than 35 000 con-
tacts held in the database of the International Symposium on
Intensive Care and Emergency Medicine, informing them of
the upcoming study. The initiative was also announced dur-
ing various international meetings and shared on social me-
dia. Study participation was voluntary.
Participants
Physicians interested in participating registered their ICU on a
secure website and received a login and password. All ICUs could
participate except those caring only for neonates. The study pro-
tocol was approved by local ethics committees when required
by local legislation or regulation. Most committees waived the
need for informed consent due to the anonymous nature of the
data collection. A few local ethics committees required written
informed consent from the patient or their next of kin.
Data Collection and Exposures
Physicians participating in the study (or their delegate such as
a trained research nurse or coordinator) were asked to record
data for all patients treated at their ICU during the 24-hour pe-
riod commencing at 08:00 (local time) on September 13, 2017.
There were no exclusion criteria. Data were collected on pre-
printed case report forms by the attending intensivist or del-
egate (other physician or a trained research nurse or coordi-
nator) and then entered electronically by the local investigators.
Centers with limited internet access were able to send the com-
pleted paper forms to the coordinating center for data entry.
The case report form included 4 sections: (1) center de-
mographics (characteristics of the hospital and the ICU and the
availability of certain diagnostic, monitoring, and therapeu-
tic techniques and interventions); (2) individual patient de-
mographics (age, sex, height, weight, date of hospital and ICU
admission, source of admission, and primary and comorbid di-
agnoses); (3) study day variables (interventions and variables
measured or occurring only during the 24-hour study day, in-
cluding 24-hour minimum and maximum hemodynamic, re-
spiratory, and laboratory parameters, therapeutic interven-
tions, presence of infection [as determined by the treating
physician], type of infection, isolated microorganisms [these
could be added later when the culture results related to any
infections the patient had on the study day became avail-
able], antibiotics received, and presence of a documented de-
cision in the patient’s notes not to resuscitate or to withhold
or withdraw life-sustaining measures); and (4) follow-up data
on November 13, 2017 (date of ICU and hospital discharge [if
no longer hospitalized] and date of ICU or hospital death).
The study definitions were provided in the case report form
and appear in the Supplement. Closed ICUs were defined as
those in which only ICU physicians could write orders. Vol-
ume in the ICU was defined as the number of admissions dur-
ing the year prior to inclusion in the study (ie, 2016). If an in-
fection was considered present, investigators were asked to
indicate whether it was definite, probable, or possible per defi-
nitions from the International Sepsis Forum,9 and its mode of
Key Points
Question What was the prevalence of infection and the hospital
mortality rate in intensive care units (ICUs) worldwide in 2017?
Findings In a 24-hour point prevalence study conducted at 1150
centers in 88 countries on September 13, 2017, 54% of patients in the
ICU had suspected or proven infection; 70% of all patients were
receiving at least 1 antibiotic (prophylactic or therapeutic). Hospital
mortality was 30% in patients with proven or suspected infection.
Meaning Among a worldwide sample of patients in ICUs in 2017,
the prevalence of suspected or proven infection was 54%.
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acquisition (in the community, at the hospital or health care–
associated, or in the ICU). Antibiotics received on the study day
(prophylactic and therapeutic) were recorded.
Because source data verification was not practical in this
globalstudy,thefollowingstepsweretakentooptimizedataqual-
ity: (1) the case report forms were built based on the forms used
in the earlier EPIC studies; (2) the case report forms were dis-
cussed at several investigator meetings; (3) plausible maximum
and minimum limits were set for each variable on the electronic
forms to prevent erroneous values being entered and investiga-
tors were contacted regarding outliers or excessive numbers of
missing values; and (4) the central coordinating center was avail-
able to all participants by email or telephone to answer any que-
ries prior to and during data collection and follow-up.
Outcomes
The main outcome measure was prevalence of infection. Ad-
ditional outcome measures were antibiotic exposure, all-
cause mortality at hospital discharge censored at 60 days, ICU
mortality, and ICU and hospital lengths of stay.
Statistical Analysis
Clinical characteristics were summarized as mean and SD,
mean and 95% CI, and median and interquartile range (IQR)
as appropriate or number and percentage for categorical fac-
tors. Missing data represented less than 5% of collected data.
Imputation of missing data was not performed. For the de-
scriptive statistics, valid percentages (ie, not including miss-
ing data) were used.
The world was divided into 7 geographical regions: North
America, Central and South America, Western Europe, Eastern
Europe, Asia and the Middle East, Australasia, and Africa as
in the EPIC II study.8 Individual countries were classified into
3 income groups according to the 2017 gross national income
per capita using thresholds defined by the World Bank atlas
method10: low to lower-middle gross national income: $3895
or less; upper-middle income: $3896 to $12 055; and high in-
come: greater than $12 055.
To estimate associations of patient characteristics, ICU or-
ganizational factors, and gross national income per capita with
infection and in-hospital death, we used a 3-level technique
with the structure of a patient (level 1) admitted to a hospital
(level 2) within a country (level 3). Thus, patients were nested
within hospitals within countries. The random-effects model
included hospital and country units to express the concept that
patients from the same country and treated at the same hos-
pital share a common environment.
The dependency between patients treated at a hospital
within a country was captured through the use of the ran-
dom intercepts. Three such analyses were conducted in (1) all
patients (with suspected or proven infection as the depen-
dent variable); (2) patients with suspected or proven infec-
tion and positive cultures (with hospital mortality as the de-
pendent variable and all microorganisms as independent
variables); and (3) patients with suspected or proven infec-
tion and positive cultures (with hospital mortality as the de-
pendent variable and antibiotic-resistant microorganisms as
independent variables).







The gray areas indicate no participating centers. EPIC III indicates Extended Study on Prevalence of Infection in Intensive Care III.
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The explanatory variables considered in the models were
(1) patient level (age, sex, Simplified Acute Physiology Score
[SAPS] II [calculated from the study day variables], type of ad-
mission [surgical, medical, or trauma], source of admission
[operating room or recovery, emergency department or am-
bulance, other hospital or hospital floor], duration of ICU stay
prior to the study day, treatment with mechanical ventilation
or kidney replacement therapy, any comorbidity, Sequential
Organ Failure Assessment score on the study day, mode of ac-
quisition of infection [in the community, at the hospital or
health care–associated, or in the ICU], and microorganisms),
(2) center level (type of hospital [university or nonuniversity]
and ICU volume); and (3) country level (gross national in-
come per capita). Missing cases for the included variables were
analyzed using the missing-value indicator method.
For the multilevel analyses, only microorganisms that had
a P value <.20 in the bivariable analysis were introduced in the
final model. Collinearity between variables was checked by in-
spection of the correlation between them and by looking at the
correlation matrix of the estimated parameters. The results of
the fixed-effects model are given as odds ratios (ORs) and 95%
CIs and also with the 80% interval OR for the constant within-
cluster fixed effects. Random-effects measures included the
variance, its SE, and the median OR. The restricted maxi-
mum likelihood procedure, which gives unbiased estimates of
the model parameters, was used. The statistical significance
of covariates was calculated using the likelihood ratio test.
The statistical analysis was performed by the coordinat-
ing center (Erasme Hospital, Brussels, Belgium) using SPSS ver-
sion 24.0 (IBM) and R version 3.2.3 (R Foundation for Statis-
tical Computing). All reported P values are 2-sided and a P value
<.05 was considered to indicate statistical significance.
Results
Patients
A total of 1150 centers participated from 88 countries (Figure 1
and eAppendix 2 in the Supplement) and 15 302 patients were
included (median, 10 patients [IQR, 6-18 patients] per cen-
ter). For the analysis, we only included the data obtained from
the 15 202 adult patients (aged ≥18 years; Figure 2). The mean
age was 61.1 years (SD, 17.3 years), 9181 were men (60.4%), and
8302 of 15 189 patients were medical admissions (55%). Ad-
mission to the ICU occurred through the emergency depart-
ment for 5002 of 15 179 patients (33%). On the study day, 6658
of 14 991 patients (44%) required invasive mechanical venti-
lation, 4234 of 15 202 (28%) required vasopressor therapy, and
1669 of of 14 917 (11%) required kidney replacement therapy.
The median length of ICU stay before the study day was 3 days
(IQR, 1-10 days) and the total median length of ICU stay was
10 days (IQR, 3-28 days).
Participating Centers
Most of the centers (645 [56%]) were in countries with high
gross national income per capita (Table 1). The countries that
included the most patients were China (11%), the UK (11%), and
Brazil (9%). Sixty-five percent of the ICUs (n = 750) were within
university hospitals. The median number of ICU beds was 12
(IQR, 8-20 beds). Most ICUs (922 [80%]) were closed units.
Figure 2. Diagram Showing the Numbers of Centers That Contributed Patient Data and the Number of Patients
With Infection
1701 Individual centers interested in participating
1150 Centers submitted patient data and case
report forms completed for 15 302 patients
551 Centers withdrew interest prior to study day (double
registration, failure to obtain ethics committee
permission in time, lack of research personnel,
information technology problems, data privacy
concerns, natural disaster affecting hospital)
100 Patients excluded (aged <18 y)
15 165 Case report forms with data for the infection section
37 Case report forms without data for the infection section
8135 Had suspected or proven infectiona




15 202 Adult patients included
a The division into definite, probable,
or possible was not provided by the
investigators for 52 patients
(missing data).
b Categorization was made by local
investigators according to
definitions from the International
Sepsis Forum.9
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Seventy-four percent of the ICUs were mixed medical-
surgical units (n = 852).
Among 1144 ICUs, an infectious disease specialist or a clini-
cal microbiologist was available 24 hours per day and 7 days
per week in 673 (59%) but was never available in 114 (10%)
(Table 2). A pharmacist (full-time or part-time) was assigned
to the ICU at 627 of 1143 centers (55%). Of 1142 ICUs, 1096 (96%)
were often or always able to perform blood cultures within
1 hour of ICU admission. Of 1143 ICUs, 1057 (93%) were often
or always able to perform qualitative respiratory cultures and
881 (77%) were often or always able to perform quantitative
respiratory cultures. Therapeutic drug monitoring was per-
formed often or always for vancomycin in 797 of 1142 ICUs
(70%) and for voriconazole in 180 of 1140 ICUs (16%).
Prevalence and Characteristics of Infections
The infection section of the case report form was completed
for 15 165 patients (99%). Of these patients, 10 640 (70%) were
receiving at least 1 antibiotic on the study day (4217 of 15 165
patients [28%] were receiving prophylactic antibiotics and 7723
of 15 165 patients [51%] were receiving therapeutic antibiot-
ics). The most frequently used prophylactic antibiotics were
cephalosporins (2144/4217 [51%]) and the most frequently used
therapeutic antibiotics were penicillins (2751/7723 [36%])
(eTable 1 in the Supplement). Of the 15 165 patients, 8135 (54%)
had at least 1 suspected or proven infection on the study day
(Table 3) and 1921 (24%) of these patients had more than 1 sus-
pected or proven infection.
The proportion of patients with suspected or proven in-
fection on the study day ranged from 43% (141/328) in
Australasia to 60% (1892/3150) in Asia and the Middle East
(eTable 2 in the Supplement). The prevalence rates for infec-
tion were 58% (385/666) among patients from countries with
low to lower-middle gross national income per capita, 59%
(3232/5498) among patients from countries with upper-
middle gross national income per capita, and 50% (4518/
9001) among patients from countries with high gross na-
tional income per capita (eTable 2 in the Supplement).
When recorded, infection was considered definite in 5419
patients (67%), probable in 1875 (23%), and possible in 789 (10%)
(Table 3). In the 7904 patients for whom it was recorded, infec-
tion was considered as acquired in the community by 3474 pa-
tients (44%), at the hospital or health care–associated by 2724
(35%), and in the ICU by 1706 (22%) (Table 3). The site of infec-
tion was the respiratory tract in 60% of patients (n = 4893), the
abdomen in 18% (n = 1490), and in the bloodstream in 15%
(n = 1239) (Table 3); these percentages varied across geographi-
cal regions (eTable 3 in the Supplement).
Table 1. Number of Centers and Patients With Listed Characteristics
Characteristic
No. (%)a
Centers (n = 1150) Patients (n = 15 302)
Regionb
Western Europe 479 (41.7) 6293 (41.1)
Central and South America 226 (19.7) 2569 (16.8)
Asia and the Middle East 217 (18.9) 3195 (20.9)
Eastern Europe 133 (11.6) 1361 (8.9)
North America 45 (3.9) 1229 (8.0)
Africa 35 (3.0) 324 (2.1)
Australasia 15 (1.3) 331 (2.2)
Gross national income per capita for 2017
Low to lower middle (≤$3895) 73 (6.3) 679 (4.4)
Upper middle ($3896-$12 055) 432 (37.6) 5557 (36.3)
High (>$12 055) 645 (56.1) 9066 (59.2)
Type of hospital
University or academic 750 (65.2) 10 898 (71.2)
Nonuniversity 400 (34.8) 4404 (28.8)
Type of ICU
Closed 922 (80.2) 12 245 (80.0)
Open 228 (19.8) 3057 (20.0)
High dependency unit within the hospitalc 469 (40.8) NA
Beds, median (IQR) 8 (6-16) NA
ICU specialty
Mixed medical-surgical 852 (74.1) 11 821 (77.3)
Surgical 160 (13.9) 1993 (13.0)
Medical 127 (11.0) 1446 (9.4)
Otherd 11 (1.0) 42 (0.3)
ICU, median (IQR)
Beds 12 (8-20) NA
Admissions in 2016 723 (430-1226) NA
Abbreviations: ICU, intensive care
unit; IQR, interquartile range;
NA, not applicable.
a Unless otherwise indicated.
b The world was divided into these
geographical regions as in the
Extended Prevalence of Infection in
Intensive Care (EPIC II) study.8
c Patients need more care than on a
normal ward, but less than in an ICU.
d Included infectious diseases,
pediatric, and obstetric.
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Among the 8135 patients with suspected or proven infec-
tion, 5259 (65%) had at least 1 positive microbiological cul-
ture and 44% of these patients had more than 1 positive cul-
ture (eTable 4 in the Supplement). Among the patients with
positive microbiological cultures, 3540 (67%) had a gram-
negative microorganism, 1946 (37%) had a gram-positive mi-
croorganism, and 864 (16%) had a fungal microorganism.
Gram-negative microorganisms were isolated in 57% (1118/
1972) of patients with culture-positive infections acquired in
the community, 71% (1281/1813) of patients with culture-
positive infections acquired at the hospital or health care–
associated, and 78% (1074/1379) of patients with culture-
positive infections acquired in the ICU (eTable 5 in the
Supplement). Gram-negative microorganisms were most
prominent in Eastern Europe (418 of 537 patients [78%]), in
Africa (93 of 120 patients [78%]), and in Asia and the Middle
East (922 of 1207 patients [76%]) (eTable 4 in the Supple-
ment). Among the 3540 patients who had gram-negative mi-
croorganisms identified on culture, the most common were
Klebsiella species (973 patients [27%]), Escherichia coli (902 pa-
tients [25%]), Pseudomonas species (850 patients [24%]), and
Acinetobacter species (602 patients [17%]) (eTable 4 in the
Supplement).
Gram-positive microorganisms were isolated in 42% (831/
1972) of patients with culture-positive infections acquired in
the community, 37% (663/1813) of patients with infections ac-
quired at the hospital or health care–associated, and 31% (432/
1379) of patients with infections acquired in the ICU (eTable 5
in the Supplement). Gram-positive microorganisms were most
prominent in North America (182 of 396 patients [46%]). Of
Table 2. Available Resources in the Participating Intensive Care Units (ICUs)
Resource
No. (%) by gross national income per capitaa
Low to lower middle (n = 73) Upper middle (n = 432) High (n = 645)
Therapeutic and monitoring techniques
High-flow nasal oxygen 39 (53.4) 275 (63.8) 557 (86.9)
Noninvasive mechanical ventilation 73 (100.0) 427 (99.1) 640 (100.0)
Invasive mechanical ventilation 72 (98.6) 429 (99.5) 638 (99.5)
Echocardiography by ICU team 48 (65.8) 276 (64.2) 554 (86.4)
Invasive monitoring (including central venous catheter
and arterial lines)
67 (91.8) 399 (92.6) 634 (98.9)
Intermittent kidney replacement therapy (dialysis) 60 (82.2) 369 (86.0) 503 (78.6)
Continuous kidney replacement therapy 36 (49.3) 280 (65.0) 590 (92.2)
Extracorporeal membrane oxygenation
(venovenous, venoarterial, or both)
15 (20.5) 130 (30.2) 243 (38.0)
Availability of infectious diseases specialist or clinical microbiologist
At all times 30 (41.1) 203 (47.1) 440 (68.8)
Just during the week 31 (42.5) 157 (36.4) 169 (26.4)
Never 12 (16.4) 71 (16.5) 31 (4.8)
Pharmacist (full-time or part-time) assigned to the ICU team 35 (47.9) 250 (58.0) 342 (53.5)
Often or always able to perform microbiological cultures
Blood 66 (90.4) 419 (97.4) 611 (95.5)
Qualitative respiratory secretions 64 (87.7) 401 (93.3) 592 (92.5)
Quantitative respiratory secretions 50 (68.5) 349 (81.2) 482 (75.3)
Urine 68 (93.2) 407 (94.9) 613 (96.1)
Often or always able to perform task
Blood gas analysis within 1 h of ICU admission 63 (87.5) 418 (97.4) 637 (99.7)
Blood lactate within 1 h of ICU admission 51 (69.9) 384 (89.5) 636 (99.4)
Any antibiograms 55 (75.3) 384 (89.7) 559 (87.6)
Antibiotics often or always available
Piperacillin/tazobactam 59 (80.8) 383 (89.1) 633 (98.9)
Echinocandins 34 (46.6) 285 (66.3) 585 (91.5)
Tigecycline 49 (68.1) 300 (69.8) 516 (80.8)
Therapeutic monitoring often or always performed
Vancomycin 22 (30.1) 188 (43.7) 587 (91.9)
Voriconazole 3 (4.1) 34 (7.9) 143 (22.4)
β-Lactam antibiotics 8 (11.0) 47 (11.0) 61 (9.6)
Echinocandins 3 (4.1) 25 (5.8) 51 (8.0)
Aminoglycosides 0 1 (0.2) 0
a The percentages were calculated using the actual number of available results
as the denominator and not the total results (eg, if there were forms for 100
centers but only 97 had the section in question completed, the denominator
for calculating the percentages would be 97 and not 100).
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5259 patients with positive cultures, methicillin-resistant
Staphylococcus aureus was isolated in 240 patients (5%); the
highest rates were in North America (40 of 396 patients [10%])
and the lowest rates were in Western Europe (49 of 2148 pa-
tients [2%]) (eTable 4 in the Supplement). Patterns of isolated
microorganisms by site of infection appear in eTable 6 in the
Supplement.
In a multilevel analysis with suspected or proven infection
as the dependent variable, male sex, comorbid conditions
(chronic obstructive pulmonary disease, cancer, diabetes,
chronic kidney failure, HIV infection, and immunosuppres-
sion), and longer ICU stay prior to the study day were indepen-
dently associated with a higher risk of infection (eTable 7 in the
Supplement). The hospital within-country variance was 0.40
(SE, 0.04) for the occurrence of infection, which was statisti-
cally significant (P < .001), indicating that the occurrence of in-
fection was influenced by between-hospital factors after ad-
justment for patient-related factors (eTable 7 in the Supplement).
Clinical Outcomes
Of the 7936 patients with suspected or proven infection and
available outcome data, 2404 died (30%) at the hospital (eTable 1
in the Supplement). Hospital mortality rates were 32% (1666/
5290) in patients with definite infection, 29% (522/1817) in pa-
tients with probable infection, and 26% (206/779) in patients
with possible infection (Table 3). The findings for ICU mortal-
ity and ICU and hospital lengths of stay appear in Table 3.
In a multilevel analysis of patients with positive cultures
for infection (with hospital death as the dependent variable)
and including all microorganisms (as independent variables),
ICU-acquired infection was independently associated with
higher risk of in-hospital mortality compared with community-
acquired infection (OR, 1.32 [95% CI, 1.10-1.60]; P = .003). In
addition, older age; having a higher SAPS II on the study day;
having metastatic cancer, heart failure (New York Heart Asso-
ciation class III-IV), HIV infection, or cirrhosis; requiring me-
chanical ventilation or kidney replacement therapy on the
study day; and referral from the hospital ward compared with
the operating room were also independently associated with
a higher risk of in-hospital death (eTable 8 in the Supple-
ment). Infections due to Streptococcus pneumoniae were as-
sociated with a lower risk of in-hospital death (OR, 0.46 [95%
CI, 0.28-0.76]; P = .002).
In a multilevel analysis of patients with positive cultures
for infection and with hospital death as the dependent vari-
able and antibiotic-resistant microorganisms as the indepen-
dent variables (eTable 9 in the Supplement), infection with a
vancomycin-resistant Enterococcus (OR, 2.41 [95% CI, 1.43-
4.06]; P = .001), a Klebsiella species resistant to β-lactam an-
tibiotics, including third-generation cephalosporins and car-
bapenems (OR, 1.29 [95% CI, 1.02-1.63]; P = .03), or a
carbapenem-resistant Acinetobacter species (OR, 1.40 [95% CI,
1.08-1.81]; P = .01) was associated with a higher risk of in-
hospital death compared with infection with another micro-
organism. The hospital within-country and country-to-
country variations in the risk of death were statistically
significant after adjustment for other possible confounders
(eTables 8 and 9 in the Supplement).
Discussion
In this 24-hour point prevalence study conducted at 1150 par-
ticipating centers in 88 countries on September 13, 2017, the
overall rate of suspected or proven infection was 54%, which
was higher than in previous EPIC studies (45% for EPIC I [mea-
sured in 1992]7 and 51% for EPIC II [measured in 2007]8).
The effect of increased detection rates due to changes in pro-
tocols and improved technology cannot be ruled out, al-
though the proportion of patients with positive microbiologi-
cal cultures was lower than in the EPIC II study (65% vs 70%).
The proportion of patients with ICU-acquired infection was
similar to the 21% reported in the EPIC I study.7
The present data indicate that the proportions of patients
in the ICU with infection continued to vary considerably across
geographic regions. Although most of the participating cen-
ters were in Europe, the rest of the world was well repre-
sented with large numbers of centers in China and South
America; however, countries with low to lower-middle gross
national income per capita contributed just 6% of the centers
and less than 5% of the patients. The variation in prevalence
of infection was associated with patient-specific and disease-
specific factors and with process of care factors across cen-
ters. Such factors may include different ICU admission crite-
ria, lower availability of resources to adjudicate or exclude a
diagnosis of infection, low nurse-to-patient ratios, and differ-
ences in infection control and antimicrobial stewardship poli-
cies. The independent effects of each of these factors could not
be determined from this study, but process of care differ-
ences across centers and their relationship to the prevalence
of infection should be considered when planning and inter-
preting the results of clinical trials.
Gram-negative microorganisms were identified more fre-
quently than gram-positive microorganisms on culture. No spe-
cific microorganism was independently and significantly as-
sociated with a higher risk of death when considering all
patients with an infection. Older age, higher SAPS II, and co-
morbid metastatic cancer, HIV infection, and heart failure were
independently associated with a higher risk of death. This
variation was associated with patient-specific and disease-
specific factors and with process of care and country-to-
country differences. In an extended analysis of data from the
EPIC II study, the importance of hospital and ICU organiza-
tional factors on outcomes was also demonstrated.13
In terms of country-to-country variation, differences in
health care (both primary care and hospital-based) expendi-
ture, access to ICU facilities, and bed availability may play a role.
Other country-related factors may include local variations in liv-
ing conditions, nutritional status, vaccine availability, antibi-
otic availability and consumption, and poor sanitation.14 It is not
possible to determine the relevant importance of each of these
aspects from the present data but these are important consid-
erations when assessing the global burden of infection.
When considering only antibiotic-resistant microorgan-
isms, infections with vancomycin-resistant Enterococcus,
Klebsiella resistant to β-lactam antibiotics (including
third-generation cephalosporins and carbapenems), and
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carbapenem-resistant Acinetobacter species were indepen-
dently associated with an increased risk of death, highlight-
ing the association of antibiotic resistance with mortality and
the importance of good antibiotic stewardship. Carbapenem-
resistant Acinetobacter baumannii and carbapenem-resistant
or third-generation cephalosporin-resistant Enterobacteri-
aceae have been listed as critical pathogens on the World Health
Organization priority list of antibiotic-resistant bacteria for ef-
fective drug development, and vancomycin-resistant Entero-
coccus as high priority.15 These infections are associated with
high morbidity and mortality and contribute to prolonged hos-
pital stays and high hospital costs.16-19
Limitations
The study has several limitations. First, participation was en-
tirely voluntary, with no financial incentive, so that monitor-
ing of data input and accuracy could only be performed cen-
trally. Voluntary participation may also lead to participation bias.
Second, due to the study design, it was not possible to es-
tablish the time of infection onset and no information on in-
fection resolution, appropriateness of treatment selection, or
effectiveness of antibiotic choices was collected. Moreover, be-
cause this was a 24-hour point prevalence study conducted
during autumn in the northern hemisphere and during spring
in the southern hemisphere, it is possible that seasonal fac-
tors may account for some of the geographical differences. Dif-
ferences in climate within and between countries may also po-
tentially influence the types of causative microorganisms.20
Point prevalence studies are also biased by patient length of
stay, potentially resulting in an oversampling of patients with
longer ICU lengths of stay and influencing assessments of risk
for mortality.
Third, even though a large number of centers partici-
pated, the representation of each country may be heteroge-
neous in terms of the proportions of ICUs that participated, re-
sulting in a patchwork picture rather than complete global
coverage, and there may be important differences in availabil-
ity and quality of health care within some of the geographical
regions, limiting interpretation of some of the results. In ad-
dition, because of the small numbers of centers in some re-
gions, particularly regions with low to lower-middle gross na-
tional income per capita, differences in infection rates by region
and the true association with mortality are difficult to evalu-
ate because of the multiple local variations in living condi-
tions, access to medical care, local infrastructure, and facili-
ties, including for microbiological cultures.
The effect of fundamental contributors to the burden of
infection in these countries with low to lower-middle gross na-
tional income per capita, including poverty, political instabil-
ity, poorly resourced health care systems, and antibiotic avail-
ability and consumption, on the present results cannot be
determined.14 Although there was between-hospital varia-
tion in risk of infection and outcomes, it was not possible to
identify which aspects of the process of care or ICU organiza-
tion were responsible. In addition, the gross national income
per capita was used to compare countries and not a specific,
detailed economic model.
Fourth, participants were asked to categorize infection into
definite, probable, or possible categories based on the Inter-
national Sepsis Forum definitions,9 but these decisions can be
subjective so should be interpreted with caution.
Fifth, despite improved communication capabilities, which
helped to spread the news of the study, and more widespread
access to the internet, which enabled easy and secure data in-
put, many centers were unable to participate. Various rea-
sons for this were cited, including increasingly strict admin-
istrative and legislative requirements, concerns about data
privacy despite the anonymous data collection, and the need
for informed consent from patients despite the observa-
tional, noninterventional nature of the study. These factors are
likely to represent a continuing challenge for such studies in
the future, making them difficult to conduct even with finan-
cial support.
Conclusions
In a worldwide sample of patients admitted to ICUs in Sep-
tember 2017, the prevalence of suspected or proven infection
was high, with a substantial risk of in-hospital mortality.
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